Abstract: Adenoid cystic carcinoma (ACC) is the second most common salivary gland malignancy and it has a high rate of recurrences and a poor long-term prognosis. Our aim was to assess the prognostic factors in ACC and study MYB-NFIB fusion and MYB protein expression in a large retrospective cohort of 135 patients with a median follow-up of 6.3 years. The 5-and 10-year local recurrence-free survival (RFS) rate of 94% and 78%, 5-and 10-year distant metastasis survival rate of 77% and 58%, and 5-and 10-year RFS of 66% and 44%. The following features were identified as adverse prognostic factors of RFS on univariate analysis: large tumor size, solid growth pattern, increased mitoses, positive margin, American Joint Committee on Cancer clinical staging, high-grade transformation, vascular invasion, nuclear atypia, open chromatin, prominent nucleoli, and tumor necrosis. However, on multivariate analysis, only increased mitoses (Z5/10 high-power fields), any solid growth pattern, and advanced American Joint Committee on Cancer TNM staging were independent adverse predictors for RFS. MYB immunoexpression and MYB-NFIB translocation were common findings in ACC, occurring in 72% and 59% of the tested ACCs, respectively. The sensitivity and specificity of MYB immunohistochemistry in detecting MYB-NFIB fusion was relatively low at 78% sensitivity and 50% specificity. The high prevalence of alterations leading to high expression of the MYB transcription factor family suggests that targeted approaches developed to suppress the expression of these oncogenic transcription factors and/or the transcriptional activity of these proteins would be a rational therapeutic approach to investigate in ACC.
A denoid cystic carcinoma (ACC) is the second most common primary salivary gland epithelial malignancy, comprising approximately 10% of all salivary gland neoplasms and 0.6% of all head and neck cancers. 1,2 ACC may arise in major salivary glands (eg, parotid, submandibular, sublingual, and lacrimal glands) or minor salivary glands distributed throughout the upper aerodigestive tract, especially those located within sinonasal tract, oral cavity, and oropharynx, and more rarely from other sites. 1, [3] [4] [5] [6] ACC is characterized by relentless clinical course and poor long-term prognosis. The 5-year survival rate is about 55% to 89%, 3, [7] [8] [9] [10] [11] [12] while the 15-or 20-year survival is poorer, being approximately 23% to 40%. 5, 11, 12 Clinically, ACC is known for its high risk of recurrence, especially late recurrence. The rate of local recurrence and distant metastasis (DM) is 16% to 67% and 8% to 46%, respectively. 1, 9, 11, [13] [14] [15] The reported independent prognostic factors include tumor site, tumor stage, nodal status, margin status, solid pattern, lymphovascular invasion, and intraneural invasion. 3, 5, [14] [15] [16] [17] [18] [19] However, to date, only a handful of published studies have investigated the prognostic factors in ACC using multivariate analysis. A detailed clinicopathologic study investigating the prognostic impacts of various histologic features is still needed.
At the molecular level, multiple studies have reported that MYB-NFIB fusion is the genetic hallmark and key oncogenic event of ACC, affecting more than 50% of tumors. [20] [21] [22] [23] [24] The fusion leads to elevated expression levels of MYB transcripts and protein which can be demonstrated by immunohistochemistry (IHC) for MYB. 20, 21, 25 However, the existing evidence has shown that the sensitivity and specificity of MYB IHC is relatively low, being 82% and 86%, respectively, in detecting ACC, 21 and 85% and 39% in detecting MYB-NFIB fusion. 25 Moreover, it remains controversial whether the fusion carries any weight in predicting disease outcome. 26, 27 The current study describes the clinicopathologic characteristics of ACC through a meticulous review of 135 patients treated at a single tertiary cancer center. Its aims are to identify independent clinical or histologic prognostic predictors, and correlate MYB fusion and immunoexpression with clinical outcome.
MATERIALS AND METHODS

Inclusion Criteria and Pathology Review
After obtaining Institutional Review Board approval, the pathology database was searched for cases of ACC diagnosed and operated at Memorial Sloan Kettering Cancer Center (MSKCC, New York, NY) between 1985 and 2012. A total of 135 patients were identified and included in the present study. The cases were subsequently subjected to detailed histopathologic analyses. The following histomorphologic features of the primary tumors were reviewed and documented: tumor size (1 tumor section was examined per 1 cm), mitotic index, atypical mitosis, tumor necrosis, prominent nucleoli, severe nuclear atypia, apoptosis, the most common architectural pattern (eg, tubular, cribriform, and solid patterns, Figs. 1A-C), the presence and percentage of solid pattern, high-grade transformation (HGT), squamous metaplasia, vascular invasion (VI), and perineural invasion (PNI). Mitotic index was determined by counting 10 high-power fields (HPFs, Â 400, total field size 2.4 mm 2 ) with an Olympus microscope (U-DO model BX41, Olympus America Inc., Center Valley, PA) in the areas of highest concentration of mitotic figures. Microscopic margins were categorized as positive (tumor at the inked margin), close (tumor within 1 mm from the inked margin), or negative (tumor Z1 mm from the inked margin). HGT was defined as tumors with severe nuclear atypia, elevated mitotic index, prominent necrosis, and loss of biphasic ductal-myoepithelial differentiation as previously described. 28 Solid growth was defined as lobulated aggregates of tumor cells arranged in small to large nests/sheets without luminal spaces. Frequent mitotic figures, tumor necrosis and cellular atypia are often a feature seen in the solid pattern compared with the cribriform and tubular patterns. The percentage of solid pattern was calculated using the total volume of solid pattern divided by the total tumor volume. Among the 83 patients who underwent lymph node sampling/dissection at the time of the initial surgery, the total number of lymph nodes sampled, size of the largest lymph node with metastasis, as well as the presence of extranodal extension were documented.
Clinical Review
All but 1 patient were followed clinically at MSKCC. The patients' charts were reviewed for age at diagnosis, sex, site of primary tumor, clinical American Joint Committee on Cancer (AJCC) staging (seventh edition), 29 as well as adjuvant radiation, chemotherapy, and target therapy. Recurrence was determined on the basis of clinical, radiologic, and pathologic examination, and was further classified as local recurrence and DM.
MYB IHC and Fluorescence In Situ Hybridization
Immunohistochemical stain for MYB was performed on 79 ACCs, using a rabbit monoclonal antibody to v-MYB and c-MYB (clone EP769Y, dilution 1:500, ABCAM, Cambridge, MA) and the Ventana system (Ventana Medical Systems Inc., Tucson, AZ) according to the manufacturer's recommendations. A tumor was considered as MYB+ when Z5% of tumor cells exhibited nuclear staining. The percentage and intensity of MYB IHC were documented.
In addition, MYB IHC was performed on 56 control cases from different head and neck sites (5 oropharyngeal HPV-related squamous cell carcinoma (SCC), 2 basaloid SCC of upper aerodigestive tract, 8 pleomorphic adenomas, 9 salivary duct carcinomas, 6 polymorphous low-grade adenocarcinoma, 4 myoepithelial carcinoma, 3 mucoepidermoid carcinoma, 3 acinic cell carcinoma, 1 basal cell adenoma, 1 basal cell adenocarcinoma, 3 sinonasal adenocarcinoma, 2 nasopharyngeal carcinoma, 1 sinonasal rhabdomyosarcoma, 1 sinonasal high-grade neuroendocrine carcinoma, 2 metastatic carcinoma to the cervical nodes).
Thirty-four of the ACC were previously subjected to fluorescence in situ hybridization (FISH) using a treecolor probe mixed consisting of BACs for 5 0 MYB (RP11-614H6, RP11-104D9, green) and 3 0 NFIB (RP11-413D24, RP11-589C16, red) (BACPAC Resources and Wellcome trust Sanger Institute, Cambridge, United Kingdom). 23 The FISH results from these cases were previously reported by our group. 23 
Statistics
All statistical analyses were performed using R Version 3.3. The association between different clinicopathologic characteristics and the risk of lymph node metastasis were investigated with the Fisher exact test. Disease-specific survival (DSS) and recurrence-free survival (RFS) were calculated from the date of diagnosis. Survival data were available for all but 1 patient. Cases with DM and/or local recurrence diagnosed within the first 3 months of the initial surgery (n = 10) were considered as occurring at presentation and thus excluded from the analysis of RFS. Prognostic value of each clinicopathologic feature with respect to DSS/RFS was determined using the Log rank test. Variables that were significant on univariate analyses for RFS were subsequently subjected to multivariate analyses using the Cox proportional hazards model. As there were only 17 disease-related deaths in our cohort, multivariate analysis for DSS was not performed. P-values <0.05 were considered to be statistically significant. 
RESULTS
Clinicopathologic Characteristics of the Study Cohort
The clinicopathologic features of the study cohort are summarized in Table 1 . The median age at diagnosis was 54 (range, 21 to 93, interquartile range, 46 to 68). There was a female predominance with a female to male ratio of 1.9:1. The majority of the tumors (63%) originated from the minor salivary glands of oral cavity (n = 72), sinonasal tract (n = 9), nasopharynx (n = 1), and trachea (n = 3), while the remaining cases were located in the major salivary glands, including submandibular gland (n = 24, 18%), parotid gland (n = 22, 16%), lacrimal gland (n = 2, 1%), and sublingual gland (n = 2, 1%). The median tumor size was 2.5 cm (range, 0.70 to 12 cm, interquartile range, 1.7 to 3.4 cm). The tumors were staged according to the AJCC (seventh edition) 29 as follows: stage I in 32/130 (25%); stage II in 29/130 (22%); stage III in 26/130 (20%); and stage IV in 43/130 cases (33%). The majority of the patients (82%) were treated in addition to surgery with adjuvant radiation therapy. In addition, 18% of the patients had chemotherapy including 3 received tyrosine kinase inhibitors.
Histologically, cribriform growth pattern was the most common pattern seen in the tumors (72%). Solid growth pattern (Fig. 1C ), was present in 33 ACCs (24%). Among these 33 tumors, 23 contained at least 30% solid area and 17 had solid pattern as the most common architecture. HGT was noted in 16 tumors (12%). Tumors with HGT showed comedo-type tumor necrosis, brisk mitotic activity with an elevated mitotic index of Z5 per 10 HPFs (median: 15/10HPFs; mean: 20/10 HPFs, range, 5 to 60/10 HPFs), and severe nuclear atypia (Figs. 1D, E). All but 1 tumor with HGT had solid pattern, and 15 had Z30% solid growth. Five tumors with HGT exhibited focal squamous metaplasia.
PNI and positive margin were common findings in ACCs, affecting 88% and 50% of the patients, respectively. In addition, elevated mitotic index (Z5/10 HPFs), tumor necrosis, prominent nucleoli, and VI were noted in 44%, 24%, 13%, and 10% of the primary tumors. 
MYB IHC and FISH Results
MYB expression was identified in 57/79 (72%) of tested ACCs (Table 1 and Fig. 1F ). MYB immunostaining was categorized as follows: 5% to 49% tumor cells staining (n = 28, 35%), and Z50% tumor cells labeling (n = 29, 37%). The intensity of the positive immunostaining was strong in 23 (40%) tumors, moderate in 27 (47%), and weak in 7 (12%) cases. The MYB IHC showed predominant staining in the tumor's periphery in 22/57 (39%) cases. The immunostaining positivity did not differ among different growth patterns (Fisher exact test, P = 0.919). In ACCs with a tubular or cribriform pattern, in which dual epithelial and myoepithelial components could be appreciated, the MYB IHC was positive mainly in the myoepithelial cells. Five of 56 (9%) control tumors showed positive MYB immunostaining (2 oropharyngeal HPV SCC, 1 basaloid SCC, 1 nasopharyngeal carcinoma, and 1 sinonasal rhabdomyosarcoma).
Among the 34 ACCs tested for MYB-NFIB FISH, 20 (59%) were positive and 14 (41%) were negative for the translocation. The fusion status did not appear to be related to the tumor growth pattern or the site of origin (Fisher exact test, P = 0.454 and 0.477, respectively). Eleven of 20 (55%) fusion-positive and 10/14 (71%) fusion-negative tumors originated from the minor salivary glands. The MYB IHC was performed on all 34 tested with FISH. Compared with the gold standard FISH test, the sensitivity and specificity of MYB IHC were 78% and 50%, respectively.
Seven tumors were positive for MYB IHC but negative for MYB-NFIB translocation, while 4 were negative for MYB IHC but positive for the translocation (Table 2 ).
Prognosis and Predictors of Adverse Outcomes
A total of 134 patients were followed at MKSCC with a median follow-up of 6.3 years (range, 0.01 to 29.5 y). Among the 83 patients who had lymph node sampling at the time of the initial surgery, 21 (25%) had metastasis to at least 1 regional lymph node. One lymph node showed tumor involvement by direct extension. No clinical/histologic features (eg, tumor size, growth patterns, solid pattern, HGT, nuclear polymorphism, tumor necrosis, and elevated mitotic activity) predicted lymph node status (Fisher exact test, P > 0.05, Table 3 ).
Seventeen patients died of their disease. The 5-, 10-, and 20-year DSS was 96% (95% confidence interval [CI], 92%-100%), 80% (95% CI, 71%-91%), and 74% (95 CI%, 63%-88%), respectively. Thirteen of these 17 patients developed DM either at the time of presentation (n = 2) or during the course of their disease (n = 9). The other 4 patients died of unresectable local recurrence. The tumor in 9 of the fatal cases contained solid pattern; 5 showed HGT of the primary tumor. Univariate analysis using log rank test showed that tumor size, elevated mitotic index, solid growth pattern, HGT, VI, severe nuclear atypia, prominent nucleoli, and tumor necrosis were significant predictors for DSS (Table 4) .
Fifty-six patients developed recurrence during clinical follow-up (Table 5 ), including 28 with DM only, 19 with local recurrence only, and 9 with both local and distant recurrences. The 5-, 10-, and 20-year RFS was 66% (95% CI, 57%-75%), 44% (95% CI, 34%-57%), and 36% (95% CI, 26%-51%), respectively. This cohort showed a 5-and 10-year local RFS rate of 94% and 78%, 5-and 10-year DM survival rate of 77% and 58%. One patient with ACC showing a predominant cribriform pattern without solid pattern or HGT developed local recurrence 26.2 years after the initial surgery. The following features were identified as adverse prognostic factors using the log rank test of RFS: large tumor size, the presence and percentage of solid pattern, elevated mitotic index, positive margin, advanced AJCC clinical staging, HGT, VI, open chromatin, severe nuclear atypia, prominent nucleoli, and tumor necrosis (Table 5) . On multivariate analysis using Cox proportional hazards model, the presence of solid pattern, elevated mitotic index of Z5/10 HPFs and AJCC clinical staging independently predicted shorter RFS (solid pattern: hazard ratio [HR], 2.36; 95% CI, 1.31-4.23; P = 0.004; mitotic index: HR, 3.03; 95% CI, 1.65-5.56; P < 0.001; and stage: HR, 1.63; 95% CI, 1.24-2.15; P < 0.001; Fig. 2 ), while the other features failed to reach significance (P > 0.05). The prognosis did not differ significantly between ACCs with 1% to 30% of solid growth pattern and those with >30% solid area (P > 0.05, Fig. 3) .A positive MYB IHC or the presence of MYB-NFIB fusion did not predict lymph node metastasis, DSS or RFS (Tables 3-5) .
DISCUSSION
ACC is the second most common salivary gland malignancy with an annual incidence of 1200 cases in the United States. 2, 30 Clinically, the tumor is characterized by a propensity for perineural spread, relentless slow growth, high frequency of local and distal recurrence as well as poor long-term survival. 1, 5, 9, [11] [12] [13] [14] [15] 17, 18 Overall, ACC has been reported to have a 5-year survival rate of 55% to 89%, 3,7-12 15 or 20-year survival of 23% to 40%, 5, 11, 12 local recurrence rate of 16% to 67%, and DM rate of 8% to 46%. 1,9,11,13-15 The 5-and 20-year RFS in our cohort was 66% and 36%, respectively, emphasizing the tendency of ACC to develop late recurrence. The most frequent sites of ACC were reported to be in minor salivary glands of the larynx, pharynx, and oral cavity, in particular the palate. 7, 13, 18, 26, 31 However, ACC of the major salivary glands 3, 5, [14] [15] [16] [17] [18] [19] The most consistent independent predictors repeatedly identified in these studies appeared to be AJCC TNM staging and margin status. 3, 5, [14] [15] [16] 18 Additional independent adverse prognostic factors reported in a single multivariate study include female sex, older age, sinonasal or paranasal sinus location, solid pattern, LVI, and intraneural invasion. 3, [14] [15] [16] [17] Similar to prior studies, we found TNM staging to be an independent predictor for RFS. In contrast to prior reported studies, 14, 16 positive margin was not identified as an independent adverse prognostic factor in our study; this could be related to the infiltrative nature of ACC and its propensity to grow along the nerves which makes it difficult to secure a true negative margin even when it appears histologically negative.
In the study herein, lymph node metastasis was found in a significant number of patients, being 15% in the entire cohort and 25% in patients who had lymph node sampling; this seems to be higher than the reported lymph metastasis rate in typical ACC, 1, 15, 16, 28, 32 and is likely to be related to selection bias in performing lymph node sampling and referral bias as the study cohort included patients from a tertiary cancer center. Among the 21 patients who harbored nodal metastasis, the majority (13/21, 62%) were patients with intraoral or oropharyngeal ACC. None of the oropharyngeal ACC was positive for p16 and/or high risk human papillomavirus. In our cohort, it appeared that intraoral/oropharyngeal ACCs were associated with higher risk (38%) of regional metastasis compared with those from other sites (14%), which was in agreement with results from previous studies. 16, 32 Histologically, ACC is a biphasic tumor composed of ductal and myoepithelial cells, forming tubular, cribriform, and solid growth patterns. 1,2 Two early studies using univariate analysis from 1978 and 1984 have shown that 34 utilized a grading system of 0%, <50%, and >50% of solid pattern and found that grading was not a significant predictor for DSS and local recurrence in a cohort of 184 ACCs. In contrast, 2 recent multivariate analyses on 218 and 78 ACCs, respectively, have shown that the presence of any solid pattern could independently predict decreased DSS. 15, 19 In accordance with these recent studies, we found that solid architecture was an independent adverse prognostic factor for shortened RFS. However, in our cohort, the percentage of solid growth (r30% or >30%) did not carry any additional significant impact on clinical outcome. Despite the prognostic significance of solid growth pattern, in our opinion, grading ACC should not be based on the percentage of solid pattern alone for multiple reasons. First, ACC is an extremely locally aggressive tumor and seems to act at the least as an intermediate grade malignancy even in the absence of solid pattern. This is especially true when compared with other types of salivary gland malignancies. Hence the concept of a low-grade ACC seems questionable. Second, in the current study, the percentage of solid growth pattern did not seem to impact tumor prognosis and any solid growth was found to be significant. Third, the criteria in most histologic grading systems include multiple parameters (proliferative activity, growth patterns/architecture, cytology, and tumor necrosis) and are not limited to tumor growth pattern solely. Interestingly, the current study is the first to show that increased mitotic activity is an independent prognostic parameter in ACC on multivariate analysis. Hence, it is important to document mitotic count in the pathology report. PNI is notoriously common in ACC, being reported in 29% to 63% of cases, 6, 13, 17, 18, 35 and in 88% in our cohort. However, with the exception of 1 study showing an association of PNI with the extent of local disease and local recurrence, multiple previous studies have failed to reveal a significant association between PNI and clinical outcomes, for example OS, DSS, regional or DM. 6, 13, 17, 18, 35 Similarly, in our cohort, the presence of PNI did not predict OS, DSS, nodal and DM in ACC. HGT (or dedifferentiation), defined as severe nuclear atypia, brisk mitotic activity, prominent necrosis, and loss of the biphasic ductal-myoepithelial differentiation, has been reported in ACC. 28, 36, 37 Although, distinguishing solid ACC from ACC with HGT might be sometimes challenging, the aggressive histologic features of solid ACC in general appear to be extensive and exaggerated in ACC with HGT compared with solid ACC. The largest series reported of ACC with HGT was by Seethala et al 28 in 2007, which included 11 cases. In the latter study, the mitotic index in the HGT component ranged from 5 to 67 per 10 HPFs with a mean of 17 per 10 HPFs and a median of 11 per 10 HPFs, which was similar to that reported in our series (mean: 20/10 HPFs, median: 15/10 HPFs, range: 5 to 60/10 HPFs). Seethala et al 28 have reported a highly aggressive clinical course and a high propensity to lymph node metastasis (over 50%) in HGT. To our knowledge, our cohort which included 16 ACCs with HGT is the largest reported series of ACC with HGT to date. In contrast to Seethala and colleagues' study, we failed to identify any clinical significance for HGT in predicting lymph node metastasis. While ACCs with HGT were associated with an increased risk of disease-specific death and recurrence on univariate analysis, on multivariate analysis, HGT was not an independent predictor of outcome in RFS. Rather, it was the presence of elevated mitotic activity and solid pattern that independently drove clinical behavior in ACC. The fact that HGT was not an independent predictor for RFS may be explained by the small number of the cases with HGT. There were not enough disease-specific deaths to perform multivariate analysis for DSS.
Fusions involving the MYB family of oncogenes are the genetic hallmark and key oncogenic event in the majority of ACC. [20] [21] [22] [23] [24] 27, 38 The reported chromosomal translocations in ACC include t(6,9) MYB-NFIB, t(8,9) MYBL1-NFIB, and t(8,14) MYBL1-RAD51B. These fusions result in high expression of MYB or MYBL1 proteins, which act on similar downstream target genes associated with apoptosis, cell cycle control, cell adhesion, angiogenesis, and differentiation. 30 The MYB-NFIB fusion, in particular, has been identified in 57% to 86% of ACC. [20] [21] [22] [23] Moreover, MYB overexpression detected on IHC studies can be seen in fusion-positive ACCs. However, existing evidence shows that MYB immunostain has a relatively low sensitivity and specificity for MYB fusion (85% and 38%, respectively), 25 and for a diagnosis of ACC (82% and 86%, respectively). 21 Such findings were confirmed by the results in our cohort, which showed 78% sensitivity and 50% specificity of MYB IHC in detecting MYB-NFIB fusion. As a diagnostic marker, However, a recent study has shown that some MYB rearrangements drive MYB expression by positioning super-enhancer elements to the MYB locus. The hypothesis that MYB targets gene are also regulated by super-enhancer elements suggests that bromodomain inhibitors may be a rational therapeutic approach for this disease, and the authors indeed demonstrated that a bromodomain inhibitor blocked and modestly suppressed MYB expression in low-grade ACC preclinical models, 39 suggesting that MYB and its transcriptional program may be viable therapeutic targets.
CONCLUSIONS
Increased mitoses, solid growth pattern, and advanced AJCC staging are independent adverse predictors for recurrence in ACC. The mere presence of solid growth but not its percentage seems to be prognostically significant. As the currently used "grading" system of ACC is solely based on the presence of >30% solid growth, consideration should be given to change the grading scheme by factoring in mitotic rate. Whatever one's position is in regard to the controversies surrounding the grading system of ACC, pathologists need to document mitotic activity and any solid growth in their reports. MYB IHC can be positive in fusion-positive and negative ACCs and does not seem to be specific. Although there is no correlation between MYB-NFIB translocation and adverse prognostic factors, the presence of the translocation in a significant proportion of ACC (around 60%) makes it a prime target for therapy.
